Our analysis of genome sequence data from paired primary and recurrent glioma patient samples shows that low-RAD18 expression is associated with hypermutation and further hints at a role for RAD18 in suppressing TMZ-induced mutations. Here, RAD18 is linked to central nervous system cancer.